Heidi Greulich

Broad Institute — United States

Medicine · Health Sciences

52h-index37.7kcitations196works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(87), HER2/EGFR in Cancer Research(38), Cancer therapeutics and mechanisms(29), Cytokine Signaling Pathways and Interactions(25), Heat shock proteins research(22)

Publications196 total

Abstract B046: Dimerization of SLFN12 by the PDE3A-SLFN12 complex is required for velcrin-induced toxicity in cancer cells
Molecular Cancer Therapeutics·2025
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Cancer Discovery·2025· 3 citedOpen Access
A Role for RAS in V-CRK Transformation
PubMed·2025· 20 citedOpen Access
Abstract 5610: BAY 2927088: a novel treatment option for patients with NSCLC with <i>HER2</i> mutations
Cancer Research·2025
Correction: Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
PLoS Medicine·2024· 1 citedOpen Access
Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12
ACS Medicinal Chemistry Letters·2024· 5 citedOpen Access
Velcrin compounds activate the SLFN12 tRNase to induce tomoptosis
Cell chemical biology·2024· 4 cited
Velcrin molecular glues induce apoptosis in glioblastomas with high <i>PDE3A</i> and <i>SLFN12</i> expression
Neuro-Oncology Advances·2024· 3 citedOpen Access
Abstract A037: Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Molecular Cancer Therapeutics·2023· 1 cited
Abstract A159: Mechanisms of uveal melanoma sensitivity to velcrin treatment and SLFN12-mediated cancer cell death
Molecular Cancer Therapeutics·2023
EXTH-38. VELCRIN MOLECULAR GLUES INDUCE CELL DEATH IN GLIOBLASTOMAS WITH HIGH <i>PDE3A</i> AND <i>SLFN12</i> EXPRESSION
Neuro-Oncology·2023Open Access
Abstract 433: Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Cancer Research·2023
Abstract 4035: Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer
Cancer Research·2023· 4 cited
Supplementary Figures 1-7 from Mutations in the &lt;i&gt;DDR2&lt;/i&gt; Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Data from Mutations in the &lt;i&gt;DDR2&lt;/i&gt; Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Supplementary Figure Legends 1-7 from Mutations in the &lt;i&gt;DDR2&lt;/i&gt; Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Supplementary Figure Legends 1-7 from Mutations in the &lt;i&gt;DDR2&lt;/i&gt; Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Data from Mutations in the &lt;i&gt;DDR2&lt;/i&gt; Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Interview with Dr. Meyerson from Mutations in the &lt;i&gt;DDR2&lt;/i&gt; Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
Interview with Dr. Meyerson from Mutations in the &lt;i&gt;DDR2&lt;/i&gt; Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Matthew Meyerson(40), William R. Sellers(14), Gad Getz(14), Roman K. Thomas(14), Kwok‐Kin Wong(14), Wendy Winckler(12), Levi A. Garraway(12), Rameen Beroukhim(10), Stacey Gabriel(9), Pasi A. Jänne(8), Michael S. Lawrence(8), Michael J. Eck(7), Megan Hanna(7), Bruce E. Johnson(6), Barbara A. Weir(6), Scott L. Pomeroy(6), Kristian Cibulskis(6), Amit Dutt(6), Jeonghee Cho(6), Takeshi Shimamura(6)